Literature DB >> 15189518

Is right ventricular outflow tract pacing an alternative to left ventricular/biventricular pacing?

Lucie Riedlbauchová1, Josef Kautzner, Robert Hatala, Thomas A Buckingham.   

Abstract

The right ventricular apex has been used as the traditional pacing site since the development of transvenous pacing in 1959. Some studies suggest that pacing the right ventricular apex may cause remodeling and is harmful. In the past decade, there have been a multitude of studies of the hemodynamic, electrophysiological, electrocardiographic, and clinical effects of ventricular pacing at other sites. Pacing of the left ventricle singly or with biventricular pacing has emerged as an effective and safe therapy for moderate to severe congestive heart failure in patients with prolonged QRS complexes. Studies of alternate right ventricular sites, like the right ventricular outflow tract, have given mixed results. Not all patients can be treated with left ventricular pacing, which is a time-consuming and difficult procedure. Right ventricular pacing is easier and less expensive than left ventricular pacing and further study of additional right ventricular sites seems warranted.

Entities:  

Mesh:

Year:  2004        PMID: 15189518     DOI: 10.1111/j.1540-8159.2004.00549.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  3 in total

Review 1.  Right ventricular outflow tract pacing: not ready for prime-time.

Authors:  S Serge Barold; Bengt Herweg
Journal:  J Interv Card Electrophysiol       Date:  2005-06       Impact factor: 1.900

Review 2.  Controversies in pacing: indications and programming.

Authors:  Anne M Gillis; Rik Willems
Journal:  Curr Cardiol Rep       Date:  2005-09       Impact factor: 2.931

Review 3.  Innovations in Cardiac Implantable Electronic Devices.

Authors:  Khurrum Khan; Jitae A Kim; Andra Gurgu; Muzamil Khawaja; Dragos Cozma; Mihail G Chelu
Journal:  Cardiovasc Drugs Ther       Date:  2021-03-02       Impact factor: 3.947

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.